NCT00090090已完成2 期
A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 114
- 试验地点
- 7
研究概览
简要总结
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
- •at least one prior cytotoxic chemotherapy regimens
- •measurable disease
- •adequate bone marrow, liver and kidney function
- •ECOG PS 0-2
排除标准
- •prior treatment with elsamitrucin
- •prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
- •HIV positive or known AIDS syndrome
- •uncontrolled medical disease or psychiatric condition/s
研究者
研究点 (7)
Loading locations...
相似试验
终止
1 期
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.AML, AdultNCT04496999Insel Gruppe AG, University Hospital Bern2
已完成
1 期
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell LymphomasB-cell LymphomaNCT01788189University Hospital, Essen37
已完成
3 期
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNonmetastatic Castration-Resistant Prostate CancerCancer of the ProstateProstate CancerNCT02003924Pfizer1,401
Unknown
不适用
Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI TherapyEGFR Gene MutationNon Small Cell Lung CancerT790MNCT05314296N.N. Blokhin National Medical Research Center of Oncology70
已完成
3 期
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative ColitisUlcerative ColitisNCT03996369Arena Pharmaceuticals354